No connection

Search Results

EBS vs OVID

EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%
OVID
Ovid Therapeutics Inc.
NEUTRAL
Price
$2.76
Market Cap
$416.8M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
EBS
8.63
OVID
--
Forward P/E
EBS
2.69
OVID
-5.89
P/B Ratio
EBS
0.8
OVID
2.75
P/S Ratio
EBS
0.56
OVID
57.48
EV/EBITDA
EBS
3.8
OVID
-7.3

Profitability

Gross Margin
EBS
49.44%
OVID
100.0%
Operating Margin
EBS
-15.2%
OVID
-1712.12%
Profit Margin
EBS
7.08%
OVID
-240.13%
ROE
EBS
10.46%
OVID
-17.51%
ROA
EBS
5.33%
OVID
-21.82%

Growth

Revenue Growth
EBS
-23.6%
OVID
844.7%
Earnings Growth
EBS
--
OVID
--

Financial Health

Debt/Equity
EBS
1.12
OVID
0.1
Current Ratio
EBS
5.01
OVID
8.97
Quick Ratio
EBS
2.19
OVID
8.4

Dividends

Dividend Yield
EBS
--
OVID
--
Payout Ratio
EBS
0.0%
OVID
0.0%

AI Verdict

EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying
OVID NEUTRAL

OVID presents a stark contrast between deterministic financial health and speculative growth potential, highlighted by a critical Piotroski F-Score of 0/9. While the company exhibits explosive revenue growth (844.70% YoY) and maintains a very strong liquidity position (Current Ratio 8.97), its operational efficiency is severely lacking with an operating margin of -1712.12%. The massive 1-year price surge of 865% is decoupled from current fundamentals, and insider selling by the CEO suggests a lack of confidence at current valuation levels. The stock remains a high-risk speculative play driven by analyst optimism rather than financial stability.

Strengths
Explosive YoY revenue growth of 844.70%
Exceptional short-term liquidity with a Current Ratio of 8.97
Very low leverage with a Debt/Equity ratio of 0.10
Risks
Critical financial health failure indicated by a 0/9 Piotroski F-Score
Extreme valuation premium with a Price/Sales ratio of 57.48
Severe operational losses with a -1712.12% operating margin

Compare Another Pair

EBS vs OVID: Head-to-Head Comparison

This page compares Emergent BioSolutions Inc. (EBS) and Ovid Therapeutics Inc. (OVID) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile